Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations

References

• Bjornsson TD, Wagner JA, Donahue SR, Harper D, Karim A, Khouri MS, Murphy WR, Roman K, Schneck D, Sonnichsen DS, et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. Journal of Clinical Pharmacology 2003; 43: 943–967
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Human cytochrome P450 enzymes. Cytochrome P450: Structure, mechanism, and biochemistry, 3rd ed, PR Ortiz de Montellano. Kluwer Academic/Plenum, New York, NY 2005; 377–530
   Google Scholar
• Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H, Kamataki T, Funae Y. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. Journal of Pharmacology and Experimental Therapeutics 2002; 300: 298–304
   PubMed Web of Science ®Google Scholar
• Hashizume T, Mise M, Terauchi Y, O L, Fujii T, Miyazaki H, Inaba T. N-dealkylation and hydroxylation of ebastine by human liver cytochrome P450. Drug Metabolism and Disposition 1998; 26: 566–571
   PubMed Web of Science ®Google Scholar
• Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 1997; 7: 103–113
   PubMedGoogle Scholar
• Inoue S, Howgate EM, Rowland-Yao K, Shimada T, Yamazaki H, Tucker GT, Rostami-Hodjegan A. Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences. Xenobiotica 2006; 36: 499–513
   PubMed Web of Science ®Google Scholar
• King LM, Gainer JV, David GL, Dai D, Goldstein JA, Browne NJ, Zelden DC. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenetics and Genomics 2005; 15: 7–13
   PubMedGoogle Scholar
• King LM, Ma JX, Srettabunjong S, Graves J, Bradbury JA, Li LP, Spiecker M, Liao JK, Mohrenweiser H, Zeldin DC. Cloning of CYP2J2 gene and identification of functional polymorphisms. Molecular Pharmacology 2002; 61: 840–852
   PubMed Web of Science ®Google Scholar
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–685
   PubMed Web of Science ®Google Scholar
• Lee SS, Jeong H-E, Liu K-H, Ryu J-Y, Moon T, Yoon CN, Oh SJ, Yun C-H, Shin J-G. Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenetics and Genomics 2005; 15: 105–113
   PubMed Web of Science ®Google Scholar
• Lin YS, Dowling ALS, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Molecular Pharmacology 2002; 62: 162–172
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Hirama T, Kim HJ, Nagata K, Yamazoe Y. In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: Different contribution of CYP2J2 in the small intestine and liver. Xenobiotica 2003; 33: 615–623
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Hirama T, Matsubara T, Nagata K, Yamazoe Y. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metabolism and Disposition 2002; 30: 1240–1245
   PubMed Web of Science ®Google Scholar
• Nelson DR, Zeldin DC, Hoffman SMG, Maltais LJ, Wain HM, Nebert DW. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004; 14: 1–18
   PubMedGoogle Scholar
• Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry 1964; 239: 2370–2378
   PubMed Web of Science ®Google Scholar
• Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 ‘pie’. Drug Metabolism and Disposition 2006; 34: 880–886
   PubMed Web of Science ®Google Scholar
• Parikh A, Gillam EMJ, Guengerich FP. Drug metabolism by Escherichia coli expressing human cytochromes P450. Nature Biotechnology 1997; 15: 784–788
   PubMed Web of Science ®Google Scholar
• Rendic S. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metabolism Reviews 2002; 34: 83–448
   PubMed Web of Science ®Google Scholar
• Scarborough PE, Ma J, Qu W, Zeldin DC. P450 subfamily CYP2J and their roles in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metabolism Reviews 1999; 31: 205–234
   PubMed Web of Science ®Google Scholar
• Shimada T, Tsumura F, Yamazaki H. Prediction of human microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone using kinetic parameters of recombinant cytochrome P450 enzymes. Drug Metabolism and Disposition 1999; 27: 1274–1280
   PubMed Web of Science ®Google Scholar
• Shimada T, Tsumura F, Yamazaki H, Guengerich FP, Inoue K. Characterization of (±)-bufuralol 1′-hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6 gene. Pharmacogenetics 2001; 11: 143–156
   PubMedGoogle Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, Node K, Borgel J, Mugge A, Lindpaintner K, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004; 110: 2132–2136
   PubMed Web of Science ®Google Scholar
• Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachisonic acid epoxygenase highly expressed in heart. Journal of Biological Chemistry 1996; 271: 3460–3468
   PubMed Web of Science ®Google Scholar
• Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T. CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metabolism and Pharmacokinetics 2004; 19: 120–129
   PubMedGoogle Scholar
• Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Saito T, Parkinson A, Nakagawa K, Kamataki T. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: Lack of co-regulation of the expression of CYP3A in Japanese livers. Xenobiotica 2005; 35: 69–83
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Nakano M, Imai Y, Ueng Y-F, Guengerich FP, Shimada T. Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Archives of Biochemistry and Biophysics 1996; 325: 174–182
   PubMed Web of Science ®Google Scholar